HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,322,292 | +2.0% | 113,149 | -3.6% | 0.01% | +16.7% |
| Q2 2023 | $4,235,880 | -10.4% | 117,435 | -5.1% | 0.01% | -14.3% |
| Q1 2023 | $4,726,624 | -39.8% | 123,766 | -10.4% | 0.01% | -44.0% |
| Q4 2022 | $7,856,638 | +41.1% | 138,078 | -1.9% | 0.02% | +38.9% |
| Q3 2022 | $5,568,000 | -12.9% | 140,812 | -3.1% | 0.02% | +5.9% |
| Q2 2022 | $6,391,000 | -15.1% | 145,256 | -23.0% | 0.02% | +6.2% |
| Q1 2022 | $7,525,000 | -0.8% | 188,700 | 0.0% | 0.02% | +6.7% |
| Q4 2021 | $7,588,000 | -0.4% | 188,700 | +0.7% | 0.02% | -6.2% |
| Q3 2021 | $7,619,000 | -10.4% | 187,300 | 0.0% | 0.02% | -11.1% |
| Q2 2021 | $8,505,000 | +9.9% | 187,300 | +0.9% | 0.02% | +12.5% |
| Q1 2021 | $7,738,000 | -8.4% | 185,600 | -6.2% | 0.02% | -20.0% |
| Q4 2020 | $8,452,000 | +39.7% | 197,900 | -14.1% | 0.02% | +33.3% |
| Q3 2020 | $6,052,000 | +3.6% | 230,300 | +5.7% | 0.02% | -6.2% |
| Q2 2020 | $5,842,000 | +56.3% | 217,900 | +4.9% | 0.02% | +33.3% |
| Q1 2020 | $3,737,000 | -1.6% | 207,700 | -3.0% | 0.01% | +20.0% |
| Q4 2019 | $3,796,000 | +14.3% | 214,100 | 0.0% | 0.01% | +11.1% |
| Q3 2019 | $3,321,000 | +6.6% | 214,100 | +18.1% | 0.01% | 0.0% |
| Q2 2019 | $3,115,000 | +11.8% | 181,300 | +4.8% | 0.01% | +12.5% |
| Q1 2019 | $2,785,000 | +48.1% | 173,000 | +34.6% | 0.01% | +33.3% |
| Q4 2018 | $1,880,000 | -18.6% | 128,500 | +1.1% | 0.01% | 0.0% |
| Q3 2018 | $2,309,000 | +7.7% | 127,100 | 0.0% | 0.01% | 0.0% |
| Q2 2018 | $2,144,000 | -7.2% | 127,100 | +7.8% | 0.01% | -14.3% |
| Q1 2018 | $2,310,000 | -3.3% | 117,900 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $2,389,000 | +71.9% | 117,900 | +47.4% | 0.01% | +75.0% |
| Q3 2017 | $1,390,000 | +35.5% | 80,000 | 0.0% | 0.00% | +33.3% |
| Q2 2017 | $1,026,000 | -78.7% | 80,000 | -84.0% | 0.00% | -82.4% |
| Q4 2014 | $4,825,000 | +103.9% | 500,000 | +92.3% | 0.02% | +88.9% |
| Q3 2014 | $2,366,000 | – | 260,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |